CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab
Condition(s):Wet Age-related Macular Degeneration (Wet AMD)Last Updated:February 15, 2017Withdrawn
Hide Studies Not Open or Pending
Condition(s):Wet Age-related Macular Degeneration (Wet AMD)Last Updated:February 15, 2017Withdrawn
Condition(s):Wet Age-related Macular DegenerationLast Updated:March 8, 2022Completed
Condition(s):Ophthalmopathy; Wet Macular DegenerationLast Updated:July 29, 2021Completed
Condition(s):Wet Macular DegenerationLast Updated:February 16, 2021Completed
Condition(s):Age-Related Macular DegenerationLast Updated:June 22, 2017Completed
Condition(s):Eye Diseases; Macular Degeneration; Retinal Diseases; Retinal Degeneration; Neovascularization, PathologicLast Updated:November 6, 2017Completed
Condition(s):Age Related Macular DegenerationLast Updated:August 28, 2012Completed
Condition(s):Age-Related Macular DegenerationLast Updated:October 10, 2012Completed
Condition(s):Neovascular Age-related Macular DegenerationLast Updated:October 26, 2023Completed
Condition(s):Wet AMDLast Updated:October 12, 2018Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.